83-2271-10　［受注停止］KRIBIOLISA Insulin Aspart ELISA 1 x 96 wells　KBI2002

特徴

• Description：Enzyme Immunoassay for the quantitative determination of Insulin Aspart in serum, plasma and cell culture supernatant
• Insulin aspart is a fast-acting insulin analog marketed by Novo Nordisk as NovoLog/NovoRapid.
• It is a manufactured form of human insulin; where a single amino acid has been exchanged.
• This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream.
• As a result, it starts working in minutes,which allows one to take insulin and eat right away.
• Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus
• About the kit：
• - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％
• - Ready to use with a standard protocol with break-apart pre-coated wells
• - Validated as per US FDA guidelines for Bioassays
• - Optimized for matrix effects to ensure higher sensitivity.
• - Shelf life： 1 year
• The method employs the quantitative sandwich enzyme immunoassay technique.
• In the first step,samples and standards are pipetted into microwells.
• If Insulin Aspart i s present in samples or standards, it will form complex with Anti-Insulin Aspart antibody, which is pre-coated onto microwells.
• Inthe second step, Anti- Insulin Aspart Biotin conjugate is pipetted and incubated.
• In the third step, HRP Conjugate is pipetted and incubated.
• Free HRP conjugate will be removed by a washing step.
• In the
• f o u r t h s t e p , T M B substrate is added to microwells and color develops proportionally to the amount of Insulin Aspart present in samples or standards.
• Color development is then stopped by addition of stop solution.
• Absorbance is measured at 450 nm.